The epilepsy prescriber's guide to antiepileptic drugs

The Epilepsy Prescriber's Guide to Antiepileptic Drugs

Volumn , Issue , 2010, Pages 1-321

  Patsalos, Philip N ^a,b   Bourgeois, Blaise F D ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925144041     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511730221     Document Type: Book

References (294)

1. Chapron DJ, Sweeney KR, Feig PU, Kramer PA. Influence of advanced age on the disposition of acetazolamide. British Journal of Clinical Pharmacology 1985; 19: 363-371.
2. Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Developmental Medicine and Child Neurology 1981; 23: 761-769.
3. Holowach J, Thurston DL. A clinical evaluation of acetazolamide (Diamox) in the treatment of epilepsy in children. Journal of Pediatrics 1958; 53: 160-171.
4. Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain and Development 2002; 24: 150-154.
5. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001; 42: 746-749.
6. Oles KS, Penry K, Cole DLW, Howard G. Use of acetazolamide as an adjunct to carbamazepine in refractory partial seizures. Epilepsia 1989; 30: 74-78.
7. Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Annals of Pharmacotherapy 1996; 30: 514-519.
8. Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990; 40: 1677-1681.
9. Soderman P, Hartvig P, Fagerlund C. Acetazolamide excretion into breast milk. British Journal of Clinical Pharmacology 1984; 17: 599-600.
10. Tawil R, Moxley RT, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43: 1105-1106.
11. Vaziri ND, SaikiJ, Barton CH, Rajudin M, Ness RL. Hemodialyzability of acetazolamide. South Medical Journal 1980; 73: 422-423.
12. Watson WA, Garrelts J C, Zinn PD, Garriott J C, McLemore TL, Clementi WA. Chronic acetazolamide intoxication. Clinical Toxicology 1984; 22: 549-563.
13. Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97: 375-379.
14. Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisolone therapy in infantile spasms. Journal of Pediatrics 1983; 103: 641-645.
15. Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004; 45: 255-262.
16. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJ, Verity CM, Osborne JP; United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with viga- batrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomized trial. Lancet Neurology 2005; 4: 712-717.
17. Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, Baram TZ, Duchowny M, Hirtz D, Pellock JM, Shields WD, Shinnar S, Wyllie E, Snead OC III; American Academy of Neurology; Child Neurology Society. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62: 1668-1681.
18. Maekawa K, Ohta H, Tamai I. Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases. Neuropaediatrie 1980; 11: 80-84.
19. Tacke E, Kupferschmid C, Lang D. Hypertrophic cardiomyopathy during ACTH treatment. Klinka Padiatrika 1983; 195: 124-128.
20. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997; 38: 1270-1274
21. Callaghan N, Kenny RA, O’Neil B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1985; 48: 639-644.
22. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotheropeutics 2010; 10: 119-140.
23. Mattson RH, Cramer JA, Collins J F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study. New England Journal of Medicine 1992; 327: 765-771.
24. Patsalos PN, Berry DJ, Bourgeois BF., Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
25. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
26. Patsalos PN, Krishna S, Elyas AA, Lascelles PT. Carbamazepine and carbamazepine-10, 11-epoxide pharmacokinetics in an overdose patient. Human Toxicology 1987; 6: 241-244.
27. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2003; 2: 347-356.
28. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurology 2003; 2: 473-481.
29. Rambeck B, Salke-Treumann A, May T, Boenigh HE. Valproic acid induced carbamazepine-10, 11-epoxide toxicity in children and adolescents. European Neurology 1990; 30: 79-83.
30. Sisodiya SM, Sander JWAS, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Research 2002; 48: 217-219.
31. Anonymous. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy: Canadian Study Group for Childhood Epilepsy. Epilepsia 1998; 39: 952-959.
32. Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, Collins S., Tracy K, Kormany WN, Abdulnabi R, Riley B, Stolle J. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50: 1158-1166.
33. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. Journal of Neurology, Neurosurgery, and Psychiatry 1984; 47: 1279-1282.
34. Kinoshita M, Ikeda A, Begum T, Terada K, Shibashaki H. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. Journal of Neurological Sciences 2007; 263: 44-48.
35. Mechndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure 2003; 12: 226-228.
36. Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007; 4: 138-144.
37. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press, Guildford, UK; 2005.
38. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurologica Scandinavica 2008; 118: 69-86.
39. Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Therapeutic Drug Monitoring 1992; 14: 269-274.
40. Silva RC, Montenegro MA, Guerreiro CA, Guerreiro MM. Clobazam as add-on therapy in children with epileptic encephalopathy. Canadian Journal of Neurological Sciences 2006; 33: 209-213.
41. Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyken P, Sato S. Serum clonazepam concentrations in children with absence seizures. Neurology 1975; 23: 255-258.
42. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Journal of Clinical Psychiatry 1987; 48(Suppl): 4-11.
43. Hakeem VF, Wallace SJ. EEG monitoring of therapy for neonatal seizures. Developmental Medicine and Child Neurology 1990; 32: 858-864.
44. Mireles R, Leppik IL. Valproate and clonazepam comedication in patients with intractable epilepsy. Epilepsia 1985; 26: 122-126.
45. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press, Guildford, UK; 2005.
46. Sironi VA, Miserocchi G, De Riu PL. Clonazepam withdrawal syndrome. Acta Neurologica 1984; 6: 134-139.
47. Agurell S, Berlin A, Ferngren H, Hellstrom B. Plasma levels of diazepam after parenteral and rectal administration. Epilepsia 1975; 16: 277-283.
48. Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. British Journal of Clinical Pharmacology 1982; 13: 553-560.
49. Klotz U, Antonin KH, Brugel H, Bieck JR. Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clinical Pharmacology and Therapeutics 1977; 21: 430-436.
50. Meberg A, Langslet A, Bredesen JE, Lunde PKM. Plasma concentration of diazepam and N-desmethyldiazepam in children after a single rectal or intramuscular dose. European Journal of Clinical Pharmacology 1978; 12: 273-276.
51. Norris E, Marzouk O, Nunn A, McIntyre J, Choonari I. Respiratory depression in children receiving diazepam for acute seizures: a prospective study. Developmental Medicine and Neurology 1999; 41: 340-343.
52. Prensky AL, Raff MC, Moore MS, Schwab RS. Intravenous diazepam in the treatment of prolonged seizure activity. New England Journal of Medicine 1967; 276: 779-886.
53. Schwartz MA, Koechlin BA, Postma E, Palmer S, Krol G. Metabolism of diazepam in rat, dog and man. Journal of Pharmacology and Experimental Therapeutics 1965; 149: 423-435.
54. Shorvon S. Status epilepticus: its clinical features and treatment in children and adults. Cambridge University Press: Cambridge; 1994.
55. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA- 2-093). Neurotherapeutics 2007; 4: 88-96.
56. Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-Da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. Journal of Clinical Pharmacology 2005; 45: 1062-1066.
57. Almeida L, Potgieter JH, Maia J, Potgieter MA, Moto F, Soares-da- Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. European Journal of Clinical Pharmacology 2008; 64: 267-273.
58. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-Da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: Comparison with carbamazepine. Epilepsia 2001; 42: 600-608.
59. Elger C, Halasz P, Maia J, Almeida L, Soares-Da-Silva P, on behalf of the BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-463.
60. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-Da-Silva P, on behalf of the BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurologica Scandinavica 2009; 120: 281-287.
61. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
62. Meis J, Almeida L, Falcao A, Soares E, Mota F, Potgieter MA, Potgieter JH, Soares-Da-Silva P. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. International Journal of Clinical Pharmacology and Therapeutics 2008; 463: 119-130.
63. Meis J, Vaz-de-Silva M, Almeida L, Falcao A, Silveira P, Guimaraes S, Graziela P, Soares-Da-Silva P. Effect of food on the pharmacokinetic profile of eslicarbazepine (BIA 2-093). Drugs R D 2005; 64: 201-206.
64. Callaghan N, O’Hare J, O’Driscoll D, O’Neill B, Dally M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Child Neurology 1982; 24: 830-836.
65. Capovilla G, Beccaria F, Veggiotti P, Rubboli G, Meletti S, Tassinari CA. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. Journal of Child Neurology 1999; 14: 395-400.
66. Giaccone M, Bartoli A, Gatti G, Marchiselli R, Pisani F, Latella MA, Perucca E. Effect of enzyme-inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. British Journal of Clinical Pharmacology 1996; 41: 575-579.
67. Glaucer TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC. For the Childhood Absence Epilepsy Study Group. Ethosuximide, Valproic acid, and Lamotrigine in childhood absence epilepsy. New England Journal of Medicine 2010; 362: 790-799.
68. Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. Annals of Neurology 1980; 7: 583-584.
69. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatric Drugs 2001; 3: 379-403.
70. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
71. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews 2005; 4: CD003032.
72. Rowan AJ, Meiser JW, De-Beer-Pawlikowski N. Valproate- ethosuximide combination therapy for refractory absence seizures. Archives of Neurology 1983; 40: 797-802.
73. Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157-163.
74. Snead OC, Horsey L. Treatment of epileptic falling spells with ethosuximide. Brain Development 1987; 9: 602-604.
75. Faught E, Sachdeo RC, Remler MP, Chayasirisobhon S, Iraqui-Madoz VJ, Ramsay RE, Sutula TP, Kanner A, Harner RN, Kuzniecki R. Felbamate monotherapy for partial-onset seizures: an active- control trial. Neurology 1993; 43: 688-692.
76. French J, Smith M, Faught E, Brown L. The use of felbamate in the treatment of patients with intractable epilepsy: practice advisory. Neurology 1999; 52: 1540-1545.
77. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-283.
78. Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. Journal of Child Neurology 1995; 10: 134-136.
79. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
80. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265-1269.
81. O’Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46: 1457-1459.
82. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
83. Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Research 2006; 71: 89-101.
84. The Felbamate Study Group in Lennox-Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine 1993; 328: 29-33
85. Aweeka FT, Gottwald MD, Gambertoglio J G, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kuglar AR, Alldredge BK. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999; 40: 777-782.
86. Boucher BA, Bombassaro A, Rasmussen SN, Watridge CB, Achari R, Turlapaty P. Phenytoin prodrug 3-phosphoryloxy-methyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. Journal of Pharmacological Sciences 1989; 78: 923-932.
87. Eldon MA, Loewen GR, Voigtman RE, Holmes GB, Hunt TL, Sedman AJ. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin. Clinical Pharmacology and Therapeutics 1993; 53: 212.
88. Leppik IE, Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM, Rask CA, Turlapaty P. Pharmacokinetics and safety of a phenytoin prodrug given IV in patients. Neurology 1990; 40: 456-460.
89. Pryor FM, Gidal B, Ramsay RE, De Toledo J, Morgan RO. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42: 245-250
90. Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. Muscle and Nerve 2000; 23: 1204-1208.
91. Chadwick D, Leiderman DB, Sauermann W, Alexander J, Garofalo E. Gabapentin in generalized seizures. Epilepsy Research 1996; 25: 191-197.
92. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42: 229-236.
93. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gaba- pentin absorption and absolute bioavailability. Epilepsy Research 2000; 40: 123-127.
94. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
95. McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clinical Therapeutics 2003; 25: 1382-1406.
96. Ohman I, Vitolis S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period and lactation. Epilepsia 2005; 46: 1621-1624.
97. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
98. Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneim Forsch Drug Research 1988; 36: 830-839.
99. Wolf SM, Shinner S, Kang H, Gil KB, Moshe SL. Gabapentin toxicity in children manifesting as behavioural changes. Epilepsia 1995; 36: 1203-1205.
100. Ben-Menachem E, Biton V, J atuzis D, Abdul-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-1317.
101. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Reviews 2007; 13: 21-42.
102. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement of oral lacosa- mide in patients with partial-onset seizures. Epilepsia 2008; 49: 418-424.
103. Doty P, Rudd D, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 2007; 4: 145-148.
104. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T, on behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled study. Epilepsia 2009; 50: 443-453.
105. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy & Behavior 2009; 14: 429-431.
106. Barr PA, Buettiker VE, Antony JH. Efficacy of lamotrigine in refractory neonatal seizures. Pediatric Neurology 1999; 20: 161-163.
107. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatric Neurology 2000; 23: 160-163.
108. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Research 1997; 26: 423-432.
109. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713.
110. Frank LM, Enlow T, Holmes GL, Manesco P, Concannon S, Chen C, Womble G, Casale EJ. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999; 40: 973-979.
111. Gamble C, Williamson PR, Chadwick DW, Marson AG. A metaanalysis of individual patient responses to lamotrigine or carba- mazepine monotherapy. Neurology 2006; 66: 1310-1317.
112. Glaucer TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC. For the Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine 2010; 362: 790-799.
113. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine- associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-991.
114. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
115. Marson AG, Al-Kharusi AM, Alwaid M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study Group. The SANAD study of effect- iveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial. Lancet 2007; 369: 1000-1015.
116. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
117. Patsalos PN, Berry DJ, Bourgeois BF., Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
118. Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004; 62: 292-295.
119. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570-571.
120. Tomson T, Luef G, Sabers A, Pittschieler S, Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 67: 1297-1299.
121. Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 2006; 66(Suppl 3): S37-S45.
122. Ben-Menachem E, Falter U; for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, doubleblind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-1283.
123. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U; Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 1751-1760.
124. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam N01057 Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
125. Gallagher MJ, Eisenman LN, Brown KM, Erbayat-Altay E, Hecimovic H, Fessler AJ, Attarian HP, Gilliam FG. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004; 45: 90-91.
126. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
127. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611-1613.
128. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
129. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 2000; 85: 77-85.
130. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clinical Pharmacokinetics 2004; 43: 707-724.
131. Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Reviews in Contemporary Pharmacotherapy 2004; 13: 1-168.
132. Patsalos PN, Ghattura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 2006; 47: 1818-1821.
133. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, Shileds WD. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574-1579.
134. Rocamora R, Wagner K, Schulze-Bonhage A. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 2006; 15: 428-433.
135. Shorvon S., Lowenthal A, Janz D, Bielen E, Loiseau P; for the European Levetiracetam Study Group. Multicenter doubleblind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-1186.
136. Specchio LM, Gambardella A, Giallonardo AT, Michelucci R, Specchio N, Boero G, La Neve A. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Research 2006; 71: 32-39.
137. Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Developmental Medicine and Child Neurology 1995; 37: 682-688.
138. DiMario FJ Jr, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatric Neurology 1988; 4: 249-251.
139. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, Shader RI. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. Journal of Pharmacology and Experimental Therapeutics 1989; 250: 134-140.
140. McDermott CA, Kowalczyk AL, Schnitzler ER, Mangurten HH, Rodvold KA, Metrick S. Pharmacokinetics of lorazepam in critically ill neonates with seizures. Journal of Pediatrics 1992; 120: 479-483.
141. Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Systematic Reviews 2005; 4: CD003723.
142. Relling MV, Mulhern RK, Dodge RK, Johnson D, Pieper JA, Rivera GK, Evans WE. Lorazepam pharmacodynamics and pharmacokinetics in children. Journal of Pediatrics 1989; 114: 641-646.
143. Riviello JJ Jr, Holmes GL. The treatment of status epilepticus. Seminars in Pediatric Neurology 2004; 11: 129-138
144. Besag FM, Berry DJ, Pool F. Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. Epilepsia 2000; 41: 624-627.
145. Browne TR, Feldman RG, Buchanan RA, Allan NC, Fawcett- Vickers L, Szako GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology 1983; 33: 414-418.
146. Hurst DL. The use of methsuximide for juvenile myoclonic epilepsy. Annals of Neurology 1995; 38: 517.
147. Strong JM, Abe T, Gibbs EL, Atkinson AJ. Plasma levels of meth- suximide and N-desmethylmethsuximide during methsuximide therapy. Neurology 1974; 24: 250-255.
148. Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood seizures. Pediatrics 1991; 87: 186-189.
149. Wilder BJ, Buchanan RA. Methsuximide for refractory complex partial seizures. Neurology 1981; 31: 741-744.
150. Bell DM, Richards G, Dhillon S, Oxley J R, Cromarty J, Sander JW, Patsalos PN. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Research 1991; 10: 183-190.
151. Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatric Emergency Care 1997; 13: 92-94.
152. Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001; 57: 1036-1042.
153. Holmes GL, Riviello JJ Jr. Midazolam and pentobarbital for refractory status epilepticus. Pediatric Neurology 1999; 20: 259-264.
154. Koul RL, Aithala GR, Chacko A, Joshi R, Elbualy MS. Continuous midazolam as treatment of status epilepticus. Archives of Diseases of Childhood 1997; 76: 445-448.
155. Lahat E, Goldman M, Barr J, Eshel G, Berkovitch M. Intranasal midazolam for childhood seizures. Lancet 1998; 352: 620.
156. Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database of Systematic Reviews 2005; 4: CD003723.
157. Riviello JJ Jr, Holmes GL. The treatment of status epilepticus. Seminars in Pediatric Neurolology 2004; 11: 129-138.
158. Sheth RD, Buckley DJ, Gutierrez AR, Gingold M, Bodensteiner JB, Penney S. Midazolam in the treatment of refractory neonatal seizures. Clinical Neuropharmacology 1996; 19: 165-170.
159. Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilep- ticus. Jounal of Child Neurology 2002; 17: 106-110.
160. Bang LM, Goa KL. Spotlight on oxcarbazepine in epilepsy. CNS Drugs 2004; 18: 57-61.
161. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67: 1497-1499.
162. Gelisse P, Genton P, Kuate D, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282-1288.
163. Johannessen Landmark S, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
164. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
165. Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, Kourilsky O, Hillion D, Aldigier J C, Jungers P. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. European Journal of Clinical Pharmacology 1994; 47:161-167.
166. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy & Behavior 2004; 5: 627-635.
167. Zheng T, Clarke AL, Morris MJ, Reid CA, Petrou S, O’Brien TJ. Oxcarbazepine, not its active metabolite, potentiates GABA A activation and aggravates absence seizures. Epilepsia 2009; 50: 83-87.
168. Ahmad S, Ellis JC, Amend H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomized trial. Lancet 2006; 367: 1555-1556.
169. Appleton R, Macleod S, Maryland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database of Systematic Reviews 2008; 3: CD001905.
170. Armstrong DL, Battin MR. Pervasive seizures caused by hypoxic- ischemic encephalopathy: treatment with intravenous paraldehyde. Journal of Child Neurology 2001; 16: 915-917.
171. Bostrom B. Paraldehyde toxicity during treatment of status epilep- ticus. American Journal of Diseases in Children 1982; 136: 414-415.
172. Chin RF, Neville BG, Packham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epi- lepticus: a prospective, population-based study. Lancet Neurology 2008; 7: 696-703.
173. Curless RG, Holzman BH, Ramsay RE. Paraldehyde therapy in childhood status epilepticus. Archives of Neurology 1983; 40: 477-480.
174. Johnson CE, Vigoreaux JA. Compatibility of paraldehyde with plastic syringes and needle hubs. American Journal of Hospital Pharmacy 1984; 41: 306-308.
175. Ramsay RE. Pharmacokinetics and parenteral use of pheny- toin, phenobarbital, and paraldehyde. Epilepsia 1989; 30(Suppl 2): S1-S3.
176. Welty TE, Cloyd JC, Abdel-Monem MM. Delivery of paraldehyde in 5% dextrose and 0.9% sodium chloride injections through polyvinyl chloride IV sets and burettes. American Journal of Hospital Pharmacy 1988; 45: 131-135.
177. Boreus LO, Jalling B, Kallberg N. Phenobarbital metabolism in adults and in newborn infants. Acta Paediatrica Scandinavica 1978; 67: 193-200.
178. Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. New England Journal of Medicine 1990; 322: 364-369.
179. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985; 313: 145-151.
180. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, Paneth N, Minnigh B, Alvin J. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. New England Journal of Medicine 1999; 341: 485-489.
181. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
182. Patsalos PN, Berry DJ, Bourgeois BF., Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs-Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
183. Vining EP, Mellitis ED, Dorsen MM, Cataldo MF, Quaskey SA, Spielberg SP, Freeman J M. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80: 165-174.
184. Wilensky AJ, Friel PN, Levy RH, Comfort CF, Kaluzny SP. Kinetics of phenobarbital in normal subjects and epileptic patients. European Journal of Clinical Pharmacology 1982; 23: 87-92.
185. Wolf S, Forsythe A. Behavior disturbance, phenobarbital and febrile seizures. Pediatrics 1978; 61: 729-731.
186. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, Johnson AL, Reynolds EH. Randomized comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-713.
187. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, Reynolds EH. Phenobarbitone, phenytoin, carba- mazepine, or sodium valproate for newly diagnosed epilepsy: a randomised comparative monotherapy trial. Journal of Neurology Neurosurgery, and Psychiatry 1995; 58: 44-50.
188. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985; 313: 145-151.
189. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
190. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
191. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2003; 2: 347-356.
192. Patsalos PN, Perucca E. Clinically important interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurology 2003; 2: 473-481.
193. Reynolds EH. Chronic antiepileptic drug toxicity: a review. Epilepsia 1975; 16: 319-352.
194. Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salama M, Waegemans T, Marsden CD. Effectiveness of piracetam in cortical myoclonus. Movement Disorders 1993; 8: 63-68.
195. Koskiniemi M, van Vleyman B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonic epilepsy: a multicentre, randomised, double-blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. Journal of Neurology, Neurosurgery, and Psychiatry 1998; 64: 344-348.
196. Obeso JA, Artieda J, Quinn N, Rothwell JC, Luquin MR, Vaamonde J, Marsden CD. Piracetam in the treatment of different types of myoclonus. Clinical Neuropharmacology 1988; 11: 529-536.
197. Shorvon SD. Pyrrolidine derivatives. Lancet 2001; 358: 1885-1892.
198. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45(Suppl 6): 13-18.
199. Corrigan BW, Poole WF, Posvar EL, Strand JC, Alvey CW, Radulovic LL. Metabolic disposition of pregabalin in healthy volunteers. Clinical Pharmacology and Therapeutics 2001; 69: P18.
200. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005; 46: 1926-1936.
201. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
202. Randnitis EJ, Posver EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Journal of Clinical Pharmacology 2003; 43: 277-283.
203. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel a2-5 (alpha2 - delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 2007; 73: 137-150.
204. Kuhnz W, Koch S, Helge H, Nau H. Primidone and phenobar- bital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Developmental Pharmacology and Therapeutics 1988; 11: 147-154.
205. Leppik IE, Cloyd JC, Miller K. Development of tolerance to the side effects of primidone. Therapeutic Drug Monitoring 1984; 6: 189-191.
206. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985; 313: 145-151.
207. Nau H, Rating D, Hauser I, Jager E, Koch S, Helge H. Placental transfer and pharmacokinetics of primidone and its metabolites pheno- barbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. European Journal of Clinical Pharmacology 1980; 18: 31-42.
208. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
209. Sapin JI, Riviello JJ, Grover WD. Efficacy of primidone for seizure control in neonates and young infants. Pediatric Neurology 1988; 4: 292-295.
210. van Heijst AN, de Jong W, Seldenrijk R, van Dijk A. Coma and crystalluria: a massive primidone intoxication treated with hae- moperfusion. Journal of Toxicology and Clinical Toxicology 1983; 20: 307-318.
211. Arroyo S. Rufinamide. Neurotherapeutics 2007; 4: 155-162.
212. Cardot JM, Lecaillon JB, Czendlik C, Godbillon J. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharmacy and Drug Disposition 1998; 19: 259-262.
213. Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 20: 751-761.
214. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox- Gastaut syndrome. Neurology 2008; 70: 1950-1958.
215. McLean MJ, Schmutz M, Pozza MF, Wamil A. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 2005; 46(Suppl 6): 375.
216. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-1141.
217. Cazali N, Tran A, Treluyer JM, Rey E, d Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. British Journal of Clinical Pharmacology 2003; 56: 526-536.
218. Chiron C. Stiripentol. Neurotherapeutics 2007; 4: 123-125.
219. Chiron C, Marchand MC, Tran A, d’Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000’ 356: 1638-1642.
220. Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d’Athis P, Vincent J, Dulac O, Pons G. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. Journal of Child Neurology 2006; 21: 496-502.
221. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metabolism and Disposition 2006; 34: 608-611.
222. Kassai B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, Guerrini R, Vincent J, Dulac O, Pons G. Severe myoclonic epilepsy in infancy: a systematic review and meta-analysis of individual patient data. Epilepsia 2008; 49: 343-348.
223. Debus OM, Kurlemann G; Study group. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo- controlled add-on trial on baseline pyridoxine medication. Epilepsia 2004; 45: 103-108.
224. Doose H, Baier WK, Ernst JP, Tuxhorn I, Volzke E. Benign partial epilepsy - treatment with sulthiame. Developmental Medicine and Child Neurology 1988; 30: 683-684.
225. Freilinger M, Seidl R, Hauser E. Carbamazepine, oxcarbazepine and sulthiame in newly diagnosed benign epilepsy of childhood with rolandic spikes. Epilepsia 1997; 38(Suppl 3): 97-98.
226. Hansen JM, Kristensen M, Skovsted L. Sulthiame (Ospolot), an inhibitor of diphenylhydantoin metabolism. Epilepsia 1968; 9: 17-22.
227. Houghton GW, Richens A. Inhibition of phenytoin metabolism by sulthiame. British Journal of Pharmacology 1973; 49: 157-158.
228. Huppke P, Kohler K, Brockmann K, Stettner GM, Gartner J. Treatment of epilepsy in Rett syndrome. European Journal of Paediatric Neurology 2007; 11: 10-16.
229. Koepp MJ, Patsalos PN, Sander JWAS. Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Research 2002; 50: 277-282.
230. Kramer U, Shahar E, Zelnik N, Lerman-Sagie T, Watemberg N, Nevo Y, Ben-Zeev B. Carbamazepine versus sulthiame in treating benign childhood epilepsy with centrotemporal spikes. Journal of Child Neurology 2002; 17: 914-916.
231. Lerman P, Nussbaum E. The use of sulthiame in myoclonic epilepsy of childhood and adolescence. Acta Neurologica Scandinavica 1975: 60(Suppl): 7-12.
232. May TW, Korn-Merker E, Rambeck B, Boenigk HE. Pharmacokinetics of sulthiame in epileptic patients. Therapeutic Drug Monitoring 1994; 16: 251-257.
233. Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 2000; 41: 1284-1288.
234. Wirrell E, Sherman EM, Vanmastigt R, Hamiwka L. Deterioration in cognitive function in children with benign epilepsy of childhood with centro temporal spikes treated with sulthiame. Journal of Child Neurology 2008; 23: 14-21.
235. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995; 36(Suppl 6): S14-S21.
236. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995; 36(Suppl 6): S7-S9.
237. Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia 1997; 38(Suppl 2): S23-S27.
238. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995; 36 (Suppl 6): S10-S13.
239. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
240. So EJ, Wolff D, Graves NM, Leppik IE, Cascino GD, Pixton GC, Gustavson LE. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Research 1995; 22: 221-226.
241. Uthman B., Rowan J, Ahmann PA, Leppik I E, Schachter SC, Sommerville KW, Shu V. Tiagabine for complex partial seizures. A randomized, add-on, dose-response trial. Archives of Neurology 1998; 55: 56-62.
242. Walker MC. The mechanism of action of tiagabine. Reviews in Contemporary Pharmacotherapy 2002; 12: 213-224.
243. Wang X, Patsalos PN. The pharmacokinetic profile of tiagabine. Reviews in Contemporary Pharmacotherapy 2002; 12: 225-234.
244. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity Research 2003; 11: 556-562.
245. Biton V, Bourgeois BF. Topiramate in patients with juvenile myoclonic epilepsy. Archives of Neurology 2005; 62: 1705-1708.
246. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330-1337.
247. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger G., Karim RM. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46: 1684-1690.
248. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324-1328.
249. Groeper K, McCann ME. Topiramate and metabolic acidosis: a case series and review of the literature. Paediatric Anaesthesia 2005; 15: 167-170.
250. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000; 54: 230-232.
251. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
252. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60: 1483-1488.
253. Meador KJ, Loring DW, Vahle VJ, Ray PG, Werz MA, Fessler AJ, Ogrocki P, Schoenberg MR, Miller JM, Kustra RP. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108-2114.
254. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. British Journal of Clinical Pharmacology 2009; 68: 655-661.
255. Mula M, Trimble MR, Thompson P, Sander JW. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003; 60: 1104-1107.
256. Ohman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Research 2009; 87: 124-129.
257. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
258. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996; 46: 1678-1683.
259. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox- Gastaut syndrome. Neurology 1999; 52: 1882-1887.
260. Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate- associated pancreatitis. Epilepsia 1993; 34: 177-183.
261. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-177.
262. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465-469.
263. Glaucer TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC. For the Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine 2010; 362: 790-799.
264. Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64: 353-355.
265. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW; Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505-513.
266. Mattson RH, Cramer JA, Collins JF; Dept. of VA Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 1992; 327: 765-771.
267. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
268. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
269. Ramsey RE, Wilder BJ, Murphy JV, Holmes GL, Uthman B. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. Journal of Epilepsy 1992; 5: 55-60.
270. Sommerville KS, Dutta S, Biton V, Zhang Y, Cloyd J C, Uthman B. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing anti epileptic drugs. Clinical Drug Investigation 2003; 23: 661-670.
271. Villareal HJ, Wilder BJ, Willmore LJ, Bauman AW, Hammond EJ, Bruni J. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978; 28: 886-891.
272. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961-965.
273. Conway M, Cubbidge RP, Hoskings SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49: 108-116.
274. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119-140.
275. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
276. Patsalos PN, Duncan J S. The pharmacology and pharmacokinetics of vigabatrin. Reviews in Contemporary Pharmacotherapy 1995; 6: 447-456.
277. Ryan MF, Samy A, Young J. Vigabatrin causes profound reduction in serum alanine transferase activity. Annals of Clinical Biochemistry 1996; 33: 257-258.
278. Shields WD. Infantile spasms: little seizures, big consequences. Epilepsy Currents 2006; 6: 63-69.
279. Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Visual field constrictions. Accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196-200.
280. Wheles JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disorders 2007; 9: 353-412.
281. Wheles JW, Ramsey RE, Collins SD. Vigabatrin. Neurotherapeutics 2007; 4: 163-172.
282. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009; 50: 163-173.
283. Brackett CC, Singh H, Block J H. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 2004; 24: 856-870.
284. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31-41.
285. Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled trial of zonisamide for the treatment of refractory partial- onset seizures. Neurology 2001; 57: 1774-1779.
286. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese literature. Journal of Child Neurology 2002; 17: 87-96.
287. Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. Journal of Child Neurology 2005; 20: 212-219.
288. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Research 1998; 29: 109-114.
289. Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Research 2006; 68S; S17-S24.
290. Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohydrosis and hyperthermia. Epilepsy Research 2004; 62: 27-34.
291. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Therapeutic Drug Monitoring 1998; 29: 593-597.
292. Patsalos PN. Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005.
293. Suzuki Y, Imai K, Toribe Y, Ueda H, Yanagihara K, Shimono K, Okinaga T, Ono J, Nagai T, Matsuoka T, Tagawa T, Abe J, Morita Y, Fujikawa Y, Arai H, Mano T, Okada S. Long-term response to zonisamide in patients with West syndrome. Neurology 2002; 58: 1556-1559.
294. Suzuki Y, Nagai T, Ono J, Imai K, Otani K, Tagawa T, Abe J, Shiomi M, Okada S. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997; 38: 1035-1038.